Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Advertisements

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 1 Concept of the therapeutic index

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Intracranial targeting of high-grade gliomas

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 6 Double opposed-field irradiation of an idealized geometry

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Figure 4 Example of a patients with CUP

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 2 Haematoxylin and eosin staining

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 2 Nonmalignant tissue can be spared from radiation

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 2 The patterns of epithelial-to-mesenchymal

Figure 1 Translocations involved in multiple myeloma

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Approaches to improve CAR-T-cell therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Annie Wester, MD, MS, Jennifer T. Eyler, MD, James W. Swan, MD

Figure 2 Frequency and overlap of alterations

Figure 2 Variations between planned and delivered doses of radiation

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

Effect of optical tissue properties during real-time intraoperative optical imaging of liver metastases in humans. Effect of optical tissue properties.

CD36 expression in tissue adjacent and distal to the tumor.

Expression of the angiogenic phenotype in the 4-NQO mouse model of HNSCC. A, tissue sections containing areas of normal, hyperkeratosis, dysplasia, and.

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.212 Figure 3 Cetuximab-800CW fluorescence in a patient with EGFR-positive head and neck cancer Figure 3 | Cetuximab-800CW fluorescence in a patient with EGFR-positive head and neck cancer. a | Preoperative bright-field image of a patient with a cutaneous squamous- cell carcinoma and b | preoperative fluorescence acquisition of the same tumour 3 days after the patient received intravenous cetuximab-800CW (50 mg) (NCT01987375). The image was acquired using an open-field fluorescence imaging device (Luna; Novadaq, Ontario, Canada). c | A bright-field image of the deep surface of a resected cutaneous squamous-cell carcinoma tumour from a different patient taken 3 days after cetuximab-800CW infusion (50 mg). d | Open-field fluorescence images (obtained with Luna, Novadaq) of the same tumour depicted in c shows areas of positive fluorescence. Additional resected specimen was taken from a deeper location than that of the primary specimen; positive areas of fluorescence were detected on e | the superficial surface, but not on f | the deep surface of the additional resection margin. g | Haematoxylin and eosin staining of 5 μm sectioned tissue from a primary tumour resected from another patient with a cutaneous squamous-cell carcinoma tumour taken 3 days after intravenous administration of cetuximab-800CW (50 mg). The outlined areas denote presence of cancer (assessed by a board-certified pathologist). h | Fluorescence scan (Odyssey; Li-COR Biosciences, Lincoln, Nebraska, USA) of the adjacent cut section, with outlined areas displaying bright fluorescence intensity. Zhang, R. R. et al. (2017) Beyond the margins: real-time detection of cancer using targeted fluorophores Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.212